The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
December 5th 2023
Aotearoa, New Zealand had a mandatory adalimumab biosimilar transition from March – September 2022. A survey reveals low satisfaction with biosimilar’s quality, as well as the lack of alcoholic wipes and a support program.
November 30th 2023
November 21st 2023
Potential barriers to an interest in pediatric rheumatology include inadequate exposure and mentorship within these specialties, as well as long periods of required training and lower compensation for pediatric specialists.
With a great deal of marginalized patients navigating burdensome, chronic, heterogenetic disease today, rheumatologists are becoming more invested in what the individual needs and wants from care.
“We realize, looking at the literature and also our clinical experience, that there are significant health disparities that are well documented in literature in Latinx and Hispanic rheumatoid arthritis patients, including perceptions of increased pain, fatigue, higher risk for depression, and a history of other self-help and self-management programs,” Adena Batterman, MSW, LCSW, explained.
Improvements in GUSS, a validated tool developed to identify changes in hand osteoarthritis over time, were higher in the denosumab group when compared with placebo and the development of new erosive joints was significantly lower at week 48.
Dr Nehad Soloman provides insight on recent approvals and upcoming FDA submissions in biosimilars, including for lupus nephritis, and how they may change the course of rheumatic disease management moving forward.
Enrollment in the FIT Teens program, which began in January 2018, was paused in March 2020 to revise operations manuals, conduct remote treatment sessions to evaluate accuracy and fidelity, obtain regulatory approvals, and train staff on the new procedures.